Accessibility Menu
Acumen Pharmaceuticals logo

Acumen Pharmaceuticals(NASDAQ) ABOS

Market Cap$158.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-89%
5 Year-85%
1 Year+40%
1 Month-7%
$2.21
+3.52%
+0.07Today
Acumen Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 2.202026-07-27
Acumen Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.45%USD 2.212026-07-20
1 month-6.78%USD 2.362026-06-26
3 month-10.57%USD 2.462026-04-28
Year to date+4.27%USD 2.112025-12-31
1 year+40.13%USD 1.572025-07-25
3 year-69.99%USD 7.332023-07-28
5 year-85.23%USD 14.902021-07-28
Since inception-89.05%USD 20.102021-07-01

Acumen Pharmaceuticals Financials at a Glance

Market Cap

$158.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$113.28M

EPS (TTM)

-$1.86

P/E Ratio

-1.19

Dividend

$0.00

Beta (Volatility)

1.38 (Average)

Price

$2.21

Volume

244,610

Open

$2.19

Previous Close

$2.20

Daily Range

$2.18 - $2.25

52-Week Range

$1.19 - $3.60

Estimated Earnings Date

Aug 11, 2026

ABOS News

MoonLake

Why Shares of Acumen Pharmaceuticals Are Down Tuesday

James HalleyJul 18, 2023

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Acumen Pharmaceuticals

Acumen develops medicines for Alzheimer’s disease, aiming to slow memory loss. Its main drug targets harmful proteins in the brain. This work could help people with early-stage Alzheimer’s live more independently.

Brainy Business: Products and Services

  • Sabirnetug (ACU193): Experimental antibody drug for early Alzheimer’s; 0% of revenue (pre-commercial).
  • Enhanced Brain Delivery (EBD): Preclinical therapy to improve drug delivery to the brain; 0% of revenue.
  • Subcutaneous Sabirnetug: Injection version for easier use; 0% of revenue.

Growth and Expansion: The Acumen Adventure

  • Partnered with JCR Pharmaceuticals in July 2025 for brain delivery technology.
  • Teamed up with Halozyme in November 2023 for easier drug administration.
  • Licensed manufacturing technology from Lonza in November 2022.
  • Raised $35.75 million in March 2026 through private placement.
  • Advanced main drug to Phase 2 clinical trials in 2025.

What Makes Acumen Stand Out?

Acumen focuses on a specific toxic protein linked to Alzheimer’s, not just general brain plaques. Its partnerships help improve drug delivery and patient convenience. The company relies on outside manufacturers and holds exclusive licenses for its main drug.

Five Things You Need to Know

  • No revenue in 2025, 2024, or 2023; company is pre-commercial.
  • Net loss was $121.3 million in 2025, up 19% from 2024.
  • R&D made up 85% of 2025 operating expenses, totaling $104.9 million.
  • Cash and investments were $116.9 million as of December 31, 2025.

Bottom Line

Acumen is a single-focus biotech betting on one Alzheimer’s drug. Its future depends on clinical trial results and ongoing funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

61

CEO

Daniel J. O'Connell, MBA

Website

www.acumenpharm.com

Headquarters

Newton, MA 02465, US

ABOS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-123.07%

Return on Capital

-121.71%

Return on Assets

-84.77%

Earnings Yield

-84.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$158.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

72.23M

Volume

244.61K

Avg. Volume

443.51K

Financials (TTM)

Gross Profit

-$46.00K

Operating Income

-$114.61M

EBITDA

-$108.82M

Operating Cash Flow

-$105.55M

Capital Expenditure

-$9.00K

Free Cash Flow

-$105.55M

Cash & ST Invst.

$128.40M

Total Debt

$31.16M

Acumen Pharmaceuticals Performance Analysis

Acumen Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Acumen Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Acumen Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.06-57.5%
20232023-12-31USD -1.082.1%
20242024-12-31USD -1.7158.3%
20252025-12-31USD -2.0017.5%
Acumen Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-41.7%
Q32025-09-3035.3%
Q42025-12-314.5%
Q12026-03-3121.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$46.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$158.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.60M

N/A

Employees

61

N/A

Net Income

-$20.74M

+28.0%

EBITDA

-$19.62M

+29.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$128.40M

-13.9%

Total Debt

$31.16M

+7.5%

Accounts Receivable

$772.00K

+105.3%

Inventory

$0.00

N/A

Long Term Debt

$16.92M

-41.4%

Short Term Debt

$14.35M

+10299.3%

Return on Assets

-84.77%

N/A

Return on Invested Capital

-1.10%

N/A

Free Cash Flow

-$24.13M

+29.5%

Operating Cash Flow

-$24.13M

+29.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALECAlector, Inc.
$1.51+2.03%
SEERSeer, Inc.
$1.97+0.00%
SPROSpero Therapeutics, Inc.
$1.18-0.84%
AGENAgenus Inc.
$6.13+2.51%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%

Questions About ABOS

What is the current price of Acumen Pharmaceuticals?

Acumen Pharmaceuticals is trading at $2.20 per share.

What is the 52-week range for Acumen Pharmaceuticals?

Over the past 52 weeks, Acumen Pharmaceuticals has traded between $1.19 and $3.60.

How much debt does Acumen Pharmaceuticals have?

As of the most recent reporting period, Acumen Pharmaceuticals reported total debt of $31.16M.

How much cash does Acumen Pharmaceuticals have on hand?

Acumen Pharmaceuticals reported $51.80M in cash and cash equivalents in its most recent financial results.

What is Acumen Pharmaceuticals’s dividend yield?

Acumen Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services